TACSTD2 and breast carcinoma: Genomic profiling for luminal A tumors (by PAM50), PIK3CA mutation, BRCA status, and immune marker expression could refine the outcomes of systemic de-escalated treatments.32 The identification of new targets with tumor-specific expression, such as Trop-2, LIV-1, and HER3, or improved conjugation technologies to optimize payload/release are certainly of paramount importance to improve ADC therapy and catalyze their development toward early breast cancer.